CCND1 G870A polymorphism is associated with toxicity of methotrexate in childhood acute lymphoblastic leukemia

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 9, 2015, Pages 11594-11600

  Xue, Yao ^a   Rong, Liucheng ^a   Tong, Na ^b   Wang, Meilin ^b   Zhang, Zhengdong ^b   Fang, Yongjun ^a  

^a CHILDREN S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

CCND1; Childhood acute lymphoblastic leukemia; MTX toxicity; Polymorphism

Indexed keywords

CCND1 PROTEIN, HUMAN; CYCLIN D1; METHOTREXATE;

ALLELE; AMINO ACID SUBSTITUTION; CHILD; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; LIVER; MALE; MUTATION; ODDS RATIO; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD;

ALLELES; AMINO ACID SUBSTITUTION; CHILD; CHILD, PRESCHOOL; CYCLIN D1; DRUG RESISTANCE, NEOPLASM; FEMALE; GENOTYPE; HUMANS; LIVER; MALE; METHOTREXATE; MUTATION; ODDS RATIO; POLYMORPHISM, GENETIC; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 85013339553     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Sinnett D, Krajinovic M and Labuda D. Genetic susceptibility to childhood acute lymphoblastic leukemia. Leuk Lymphoma 2000; 38: 447-62.
2. Pui CH, Cheng C, Leung W, Rai SN, Rivera GK, Sandlund JT, Ribeiro RC, Relling MV, Kun LE, Evans WE and Hudson MM. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med 2003; 349: 640-9.
3. Widemann BC, Balis FM, Kim A, Boron M, Jayaprakash N, Shalabi A, O'Brien M, Eby M, Cole DE, Murphy RF, Fox E, Ivy P and Adamson PC. Glucarpidase, Leucovorin, and Thymidine for High-Dose Methotrexate-Induced Renal Dysfunction: Clinical and Pharmacologic Fa-ctors Affecting Outcome. J Clin Oncol 2010; 28: 3979-86.
4. Krynetski EY and Evans WE. Genetic polymorphism of thiopurine S-methyltransferase: molecular mechanisms and clinical importance. Pharmacology 2000; 61: 136-46.
5. Kim JK and Diehl JA. Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol 2009; 220: 292-6.
6. Butt AJ, Caldon CE, McNeil CM, Swarbrick A, Musgrove EA and Sutherland RL. Cell cycle machinery: links with genesis and treatment of breast cancer. Adv Exp Med Biol 2008; 630: 189-205.
7. Banerjee D, Ercikan-Abali E, Waltham M, Schnieders B, Hochhauser D, Li WW, Fan J, Gorlick R, Goker E and Bertino JR. Molecular mechanisms of resistance to antifolates, a review. Acta Biochim Pol 1995; 42: 457-64.
8. Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD and Heighway J. Alternate splicing produces a novel cyclin D1 transcript. Oncogene 1995; 11: 1005-11.
9. Millar EK, Dean JL, McNeil CM, O'Toole SA, Henshall SM, Tran T, Lin J, Quong A, Comstock CE, Witkiewicz A, Musgrove EA, Rui H, Lemarchand L, Setiawan VW, Haiman CA, Knudsen KE, Sutherland RL and Knudsen ES. Cyclin D1b protein expression in breast cancer is independent of cyclin D1α and associated with poor disease outcome. Oncogene 2009; 28: 1812-20.
10. Hou X, Wang S, Zhou Y, Xu Z, Zou Y, Zhu X, Han M, Pang T and Han ZC. Cyclin D1 gene polymorphism and susceptibility to childhood acute lymphoblastic leukemia in a Chinese population. Int J Hematol 2005; 82: 206-9.
11. Costea I, Moghrabi A and Krajinovic M. The influence of cyclin D1 (CCND1) 870A>G polymorphism and CCND1-thymidylate synthase (TS) gene-gene interaction on the outcome of childhood acute lymphoblastic leukaemia. Pharmacogenetics 2003; 13: 577-80.
12. Dulucq S, St-Onge G, Gagné V, Ansari M, Sinnett D, Labuda D, Moghrabi A and Krajinovic M. DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL. Blood 2008; 111: 3692-700.
13. Xue Y, Xu H, Rong L, Lu Q, Li J, Tong N, Wang M, Zhang Z and Fang Y. The MIF-173G/C polymorphism and risk of childhood acute lymphoblastic leukemia in a Chinese population. Leuk Res 2010; 34: 1282-6.
14. Tong N, Fang Y, Li J, Wang M, Lu Q, Wang S, Tian Y, Rong L, Sun J, Xu J and Zhang Z. Methylenetetrahydrofolate reductase polymorphisms, serum methylenetetrahydrofolate reductase levels, and risk of childhood acute lymphoblastic leukemia in a Chinese population. Cancer Sci 2010; 101: 782-6.
15. Ni J, Wang M, Wang M, Fu S, Zhou D, Zhang Z, Han S. CCND1 G870A polymorphism and cervical cancer risk: a case-control study and meta-analysis. J Cancer Res Clin Oncol 2010; 137: 489-94.
16. Bertino JR. Cancer research: from folate antagonism to molecular targets. Best Pract Res Clin Haematol 2009; 22: 577-82.
17. Treon SP and Chabner BA. Concepts in use of high-dose methotrexate therapy. Clin Chem 1996; 42: 1322-9.
18. Pui CH, Relling MV and Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004; 350: 1535-48.
19. Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Arkin S, Declerck L, Cohen HJ and Sallan SE. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001; 97: 1211-8.
20. Pitman SW and Frei E 3rd. Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma. Cancer Treat Rep 1977; 61: 695-701.
21. Krajinovic M and Moghrabi A. Pharmacoge-netics of methotrexate. Pharmacogenomics 2004; 5: 819-34.
22. Hochhauser D, Schnieders B, Ercikan-Abali E, Gorlick R, Muise-Helmericks R, Li WW, Fan J, Banerjee D and Bertino JR. Effect of cyclin D1 overexpression on drug sensitivity in a human fibrosarcoma cell line. J Natl Cancer Inst 1996; 88: 1269-75.
23. Li W, Fan J, Hochhauser D, Banerjee D, Zielinski Z, Almasan A, Yin Y, Kelly R, Wahl GM and Bertino JR. Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines. Proc Natl Acad Sci U S A 1995; 92: 10436-40.
24. Gorlick R, Goker E, Trippett T, Waltham M, Banerjee D and Bertino JR. Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 1996; 335: 1041-8.
25. Bertino JR, Göker E, Gorlick R, Li WW and Banerjee D. Resistance Mechanisms to Methotrexate in Tumors. Oncologist 1996; 1: 223-226.
26. Shimasaki N, Mori T, Samejima H, Sato R, Shimada H, Yahagi N, Torii C, Yoshihara H, Tanigawara Y, Takahashi T and Kosaki K. Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol 2006; 28: 64-8.
27. Imanishi H, Okamura N, Yagi M, Noro Y, Moriya Y, Nakamura T, Hayakawa A, Takeshima Y, Sakaeda T, Matsuo M and Okumura K. Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. J Hum Genet 2007; 52: 166-71.
28. Kantar M, Kosova B, Cetingul N, Gumus S, Toroslu E, Zafer N, Topcuoglu N, Aksoylar S, Cinar M, Tetik A and Eroglu Z. Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Leuk Lymphoma 2009; 50: 912-7.
29. Laverdière C, Chiasson S, Costea I, Moghrabi A and Krajinovic M. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 2002; 100: 3832-4.
30. Costea I, Moghrabi A, Laverdiere C, Graziani A and Krajinovic M. Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia. Haematologica 2006; 91: 1113-6.